A detailed history of Royal Bank Of Canada transactions in Zai Lab LTD stock. As of the latest transaction made, Royal Bank Of Canada holds 1,551 shares of ZLAB stock, worth $40,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,551
Previous 1,637 5.25%
Holding current value
$40,992
Previous $28,000 32.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$16.25 - $24.14 $1,397 - $2,076
-86 Reduced 5.25%
1,551 $37,000
Q2 2024

Aug 14, 2024

SELL
$13.72 - $21.55 $2,757 - $4,331
-201 Reduced 10.94%
1,637 $28,000
Q1 2024

Nov 05, 2024

BUY
$15.95 - $26.8 $2,153 - $3,618
135 Added 8.25%
1,772 $28,000
Q1 2024

May 15, 2024

SELL
$15.95 - $26.8 $22,409 - $37,654
-1,405 Reduced 43.32%
1,838 $29,000
Q4 2023

Feb 14, 2024

SELL
$22.97 - $30.58 $28,873 - $38,439
-1,257 Reduced 27.93%
3,243 $88,000
Q3 2023

Nov 14, 2023

SELL
$22.72 - $31.49 $7,997 - $11,084
-352 Reduced 7.25%
4,500 $109,000
Q2 2023

Aug 14, 2023

BUY
$25.3 - $39.67 $116,708 - $182,997
4,613 Added 1930.13%
4,852 $134,000
Q1 2023

May 15, 2023

SELL
$30.21 - $48.1 $11,872 - $18,903
-393 Reduced 62.18%
239 $7,000
Q4 2022

Feb 14, 2023

BUY
$22.28 - $38.71 $13,011 - $22,606
584 Added 1216.67%
632 $19,000
Q3 2022

Nov 14, 2022

BUY
$34.2 - $51.69 $1,470 - $2,222
43 Added 860.0%
48 $1,000
Q1 2022

May 16, 2022

SELL
$27.77 - $64.4 $3,499 - $8,114
-126 Reduced 96.18%
5 $0
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $6,368 - $12,204
116 Added 773.33%
131 $8,000
Q3 2021

Nov 15, 2021

SELL
$105.0 - $178.37 $1.05 Million - $1.79 Million
-10,025 Reduced 99.85%
15 $2,000
Q2 2021

Aug 16, 2021

BUY
$125.11 - $180.0 $1.26 Million - $1.81 Million
10,040 New
10,040 $1.78 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.59B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.